You have read all your free articles, to continue reading subscribe to read the rest of this content.
Diamyd Medical is extending its collaboration with Protein Sciences regarding the development of diabetes treatment. Following the new agreement the American firm becomes one of the larger share holders of Diamyd. Diamyd Medical and Protein Sciences Corporation have announced that Protein ScienceAlready a subscriber Login You have read all your…
The company has received regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for its upcoming phase 1/2a combination study with the company's leading candidate drug MIV-818 against liver cancer. In the study, MIV-818 will be administered in two combinAlready a subscriber Login You have read all…
The capital investment from Omnio's shareholders will be used for ongoing development work and to begin creating a blueprint for manufacturing. The company has already made a number of physician-led studies and successful trials involving patients with clinical wounds, they state in their press rAlready a subscriber Login You have…
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and havAlready a subscriber Login You have…
